According to the equation above, we can imagine the coagulation factor IX as 14 partitions with equal length, each contains 33 (461/14 = 32.
For the mutated amino acid, there are 10 Hs in normal coagulation factor IX and 11 Hs in the mutant.
Because this mutation increases the distribution probability of both the original and mutated amino acids, its overall effect obviously brings about an increment of the distribution probability in the mutant coagulation factor IX, (0.
In this manner, we have different numbers for different mutations in coagulation factor IX and their documented clinical manifestation, and we therefore can build a quantitative relationship between changed primary structure of coagulation factor IX and clinical severity of hemophilia B.
Thus, we can use the cross-impact analysis to build a quantitative relationship between the increase/decrease of distribution probability after mutations and the defined/undefined severity of hemophilia B, because the appearance/non-appearance is an event with two options, and the mutation effect on coagulation factor IX is also an event with two options as increased or decreased amino-acid distribution probability, while the cross-impact analysis is particularly suited for these [38, 48-53].